Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $1,000.00.
Mohit Bansal has given his Buy rating due to a combination of factors including the current valuation and future growth prospects of Eli Lilly & Co. Despite concerns about the impact of the International Pricing Index (IPI) on the company’s Tirzepatide franchise, Bansal believes the current stock price of Eli Lilly presents a buying opportunity due to its discounted cash flow fair value being estimated at $885 per share.
Bansal’s analysis considers the potential negative effects of pricing negotiations under the Inflation Reduction Act but sees the company entering a catalyst-rich period in 2025. He expects continuous growth driven by new market opportunities and argues that the company could effectively counteract the negative pricing impact through data-driven arguments on the preventive benefits of its drugs. This potential for future growth, even under worst-case pricing scenarios, supports his recommendation to buy the stock.
In another report released on November 19, Leerink Partners also reiterated a Buy rating on the stock with a $970.00 price target.
LLY’s price has also changed slightly for the past six months – from $783.180 to $753.410, which is a -3.80% drop .
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Eli Lilly & Co (LLY) Company Description:
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
Read More on LLY:
